CEBPB and Parkinson disease: Our group has recently demonstrated that C/EBPβ reduction in in vitro and in animal models of PD results in an amelioration of dopaminergic damage and glial activation [30], suggesting that C/EBPβ depletion could constitute a valuable new therapeutic target for PD.